<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53689">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962831</url>
  </required_header>
  <id_info>
    <org_study_id>REB-13-51</org_study_id>
    <nct_id>NCT01962831</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial: Induction of Labour of Obese Women With Dinoprostone or Single Balloon Catheter</brief_title>
  <official_title>Randomized Controlled Trial: Single Balloon Catheter Versus Dinoprostone Vaginal Insert for Induction of Labour of Women With a BMI Equal to or Greater Than 30</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Qu'Appelle Health Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regina Qu'Appelle Health Region</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of single balloon foley catheters to
      dinoprostone for the induction of labour of obese women. The investigators suspect that
      women assigned to the foley group will have a shorter induction to delivery time than women
      in the dinoprostone group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time(hours) from initiation of induction of labour to vaginal delivery</measure>
    <time_frame>Will be assessed at the end of each vaginal delivery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of vaginal deliveries within 24 hours in each group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cesarean sections in each group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of operative vaginal deliveries in each group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of chorioamnionitis cases in each group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that required oxytocin administration in each group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that required an epidural in each group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of babies that required neonatal intensive care unit (NICU) admission in each group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of babies that had an arterial pH &lt;7 in each group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of babies that had an APGAR score &lt;7 at 5 minutes</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Obesity</condition>
  <condition>Pregnancy</condition>
  <condition>Labor, Induced</condition>
  <arm_group>
    <arm_group_label>dinoprostone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of women that will receive dinoprostone for induction of labour dinoprostone 10 mg in vagina to be reassessed every 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single balloon foley catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of women that will have a single balloon foley catheter inserted for induction of labour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone</intervention_name>
    <arm_group_label>dinoprostone</arm_group_label>
    <other_name>Cervidil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Single balloon foley catheter</intervention_name>
    <arm_group_label>Single balloon foley catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparous

          -  Obese (BMI &gt;30 before 20 weeks gestational age)

          -  Singleton pregnancy

          -  Vertex presentation

          -  Bishop Score &lt;6

          -  Intact membranes

          -  Gestational age 37+0 to 42+0

          -  Normal fetal heart tracing on admission for ripening

        Exclusion Criteria:

          -  Induction of labour for intrauterine fetal demise

          -  Intrauterine growth restriction

          -  Suspected abruption at the start of induction

          -  Any contraindication for a vaginal delivery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Lett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regina Qu'Appelle Health Region</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Lett, MD</last_name>
    <phone>(306) 585-9565</phone>
    <email>cdf444@mail.usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regina Qu'Appelle Health Region</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4P0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lett</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 10, 2013</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Qu'Appelle Health Region</investigator_affiliation>
    <investigator_full_name>Dr. Christine Lett</investigator_full_name>
    <investigator_title>Clinical Assistant Professor of Obstetrics &amp; Gynecology, University of Saskatchewan</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>labor, induced</keyword>
  <keyword>pregnancy</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>dinoprostone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
